Dr. Reddy’s Laboratories has launched Raloxifene hydrochloride tablets in 60 mg, a therapeutic equivalent generic version of Evista (raloxifene hydrochloride) tablets in the United States market, approved by the U.S. Food & Drug Administration (USFDA). Dr. Reddys Raloxifene tablets are available in 60 mg in bottle count sizes of 30, 100 and 1,000.
The Evista brand and generic had U.S. sales of approximately $265 million MAT for the most recent twelve months ending in September 2016 according to IMS Health. Evista is a registered trademark of Eli Lilly and company.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1831.30 |
| Dr. Reddys Lab | 1307.00 |
| Cipla | 1361.00 |
| Zydus Lifesciences | 940.10 |
| Lupin | 2460.50 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: